t-CUPM

t-CUPM is a novel small molecule compound synthesized by modifying the central phenyl ring of sorafenib. It functions as a dual inhibitor of c-Raf and soluble epoxide hydrolase (sEH). This dual inhibition allows t-CUPM to block signals from mutant Ras to downstream pathways like MEK-ERK and to increase the ratio of anti-inflammatory and anti-pain epoxyeicosatrienoic acids (EETs) by inhibiting sEH. Preclinical studies have shown that t-CUPM significantly inhibits the growth of mutant Kras(G12D)-initiated murine pancreatic carcinoma cells both in vitro and in vivo, indicating its potential as an agent for treating pancreatic cancer.

Other names

trans-4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-cyclohexyloxy}-pyridine-2-carboxylic acid methylamide